First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac

Tomas M. Janssen*, Katharine Aitken, Filippo Alongi, Aisling Barry, Uffe Bernchou, Simon Boeke, William A. Hall, Ali Hosni, Petra S. Kroon, Marcel Nachbar, Hina Saeed, Ina M. Jürgenliemk-Schulz, Tine Schytte, Helena M. Verkooijen, Marlies E. Nowee, On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

19 Downloads (Pure)

Abstract

The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.

Original languageEnglish
JournalTechnical Innovations and Patient Support in Radiation Oncology
Volume22
Pages (from-to)50-54
ISSN2405-6324
DOIs
Publication statusPublished - Jun 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s)

Keywords

  • (3–6): oligometastases
  • MOMENTUM
  • MR-guided radiotherapy
  • MR-Linac
  • SABR

Fingerprint

Dive into the research topics of 'First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac'. Together they form a unique fingerprint.

Cite this